Evidence map›Paper›PMID 27482120›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Innate immunity kinase TAK1 phosphorylates Rab1 on a hotspot for posttranslational modifications by host and pathogen.

Rebecca S Levin, Nicholas T Hertz, Alma L Burlingame, Kevan M Shokat, Shaeri Mukherjee

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Glycosylating Effectors ofBiomolecules · 2022
    Review
  12. Article
  13. Article
  14. Proteolysis of Rab32 byiScience · 2021
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rebecca S LevinDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; Howard Hughes Medical Institute, University of California, San Francisco, CA 94158;
Nicholas T HertzDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; Howard Hughes Medical Institute, University of California, San Francisco, CA 94158;
Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; Howard Hughes Medical Institute, University of California, San Francisco, CA 94158; kevan.shokat@ucsf.edu shaeri.mukherjee@ucsf.edu.
Shaeri MukherjeeDepartment of Microbiology and Immunology, University of California, San Francisco, CA 94143 kevan.shokat@ucsf.edu shaeri.mukherjee@ucsf.edu.
University of California, San Francisco · US

Funding

RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Subversion of membrane transport pathways by Legionella pneumophilaR01AI118974 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHERJEE, SHAERI · 2016 to 2020
$2.0M
Drugging the Switch-II Pocket of K-RasR01CA190408 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOKAT, KEVAN M. · 2014 to 2018
$1.5M
NCI NIH HHS R01 CA190408NIAID NIH HHS R01 AI118974NIGMS NIH HHS P41 GM103481NIGMS NIH HHS T32 GM064337
6 · The paper itself

Abstract

TGF-β activated kinase 1 (TAK1) is a critical signaling hub responsible for translating antigen binding signals to immune receptors for the activation of the AP-1 and NF-κB master transcriptional programs. Despite its importance, known substrates of TAK1 are limited to kinases of the MAPK and IKK families and include no direct effectors of biochemical processes. Here, we identify over 200 substrates of TAK1 using a chemical genetic kinase strategy. We validate phosphorylation of the dynamic switch II region of GTPase Rab1, a mediator of endoplasmic reticulum to Golgi vesicular transport, at T75 to be regulated by TAK1 in vivo. TAK1 preferentially phosphorylates the inactive (GDP-bound) state of Rab1. Phosphorylation of Rab1 disrupts interaction with GDP dissociation inhibitor 1 (GDI1), but not guanine exchange factor (GEF) or GTPase-activating protein (GAP) enzymes, and is exclusive to membrane-localized Rab1, suggesting phosphorylation may stimulate Rab1 membrane association. Furthermore, we found phosphorylation of Rab1 at T75 to be essential for Rab1 function. Previous studies established that the pathogen Legionella pneumophila is capable of hijacking Rab1 function through posttranslational modifications of the switch II region. Here, we present evidence that Rab1 is regulated by the host in a similar fashion, and that the innate immunity kinase TAK1 and Legionella effectors compete to regulate Rab1 by switch II modifications during infection.

Indexed as

Host-Pathogen InteractionsProtein Processing, Post-TranslationalCell LineGolgi ApparatusGuanine Nucleotide Dissociation InhibitorsGuanine Nucleotide Exchange FactorsHumansImmunity, InnateLegionella pneumophilaMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesPhosphorylationrab1 GTP-Binding ProteinsGDP dissociation inhibitor 1Guanine Nucleotide Dissociation InhibitorsGuanine Nucleotide Exchange FactorsMAP Kinase Kinase Kinase 7MAP Kinase Kinase Kinasesrab1 GTP-Binding Proteinschemical geneticskinase substratesposttranslational modificationRab GTPasesvesicle trafficking

Identifiers

PMID27482120
PMCPMC4995946
OpenAlexW2498323848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.